Private equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...

This is the second pharma merger and acquisition (M&A) transaction that has been called off or postponed recently due to market volatility ...

The move comes at a time when Medlife is in the midst of a $150 million fundraising round from strategic as well as institutional investors.

In November 2017, there were 39 deals worth USD 3.2 billion.

"More clarity on the proposed structure, valuations can be expected in the next six months," a source said adding that the merger may or ma...

Infosys had lowered its dollar revenue guidance to 10.5-12% in constant currency terms from its earlier forecast of 11.5-13.5% in July.

The remedy requires Teva to divest the drug portfolio to 11 firms and marks the largest drug divestiture order in an FTC pharmaceutical mer...

Given the rupee, where it is right now, the September quarter numbers will be pretty good for pharma companies, says Shenoy.

17 of 30 Sensex stocks ended the day in red. Vedanta Ltd was the gainer on Sensex, up over 2%. Cairn India was the top loser on NSE Nifty, ...

I believe the overall stock reaction today is in view of the same. Secondly, Sun Pharma management has refrained from giving any guidance f...

"The valuations are little bit on the higher side. Clearly the growth trajectory is there for the companies and an addressable market size ...

Now if you look at the world’s top 70 drugs, 50% of them or more are made and marketed by companies that did not invent them.

The sector has slowed from its peak growth rate, the lure of expansion in the Rs 75,000-crore pharma market has kept companies looking for ...

In a chat with ET Now, Sonam Udasi, Head of Research, IDBI Capital, shares his views on pharma sector.

Indian M&A market showed moderate levels of deal activity in the first nine months of this year with 377 deals amounting to $23.9 billion.

'Besides inorganic initiatives, the industry is also stepping up its organic investments.'

Pharmaceuticals major Cipla Ltd has drawn up a Rs 2,000-crore capex plan over the next two years, a top company official said on Thursday.